B-Cell Disorders and Curcumin

Terry Golombick PhD, Dipl, Nutr; Terrence H. Diamond MB BCh, MRCP, FRACP; Arumugam Manoharan MD, FRACP, FRCPA; Rajeev Ramakrishna BMed, FRACP, FRCPA

doi:10.1177/1534735415622013

Integrative Cancer Therapies (Sep 2017)

B-Cell Disorders and Curcumin

Terry Golombick PhD, Dipl, Nutr,
Terrence H. Diamond MB BCh, MRCP, FRACP,
Arumugam Manoharan MD, FRACP, FRCPA,
Rajeev Ramakrishna BMed, FRACP, FRCPA

Affiliations

Terry Golombick PhD, Dipl, Nutr: St George Hospital, Sydney, New South Wales, Australia
Terrence H. Diamond MB BCh, MRCP, FRACP: St George Hospital, Sydney, New South Wales, Australia
Arumugam Manoharan MD, FRACP, FRCPA: University of Wollongong, Wollongong, NSW, Australia
Rajeev Ramakrishna BMed, FRACP, FRCPA: University of Wollongong, Wollongong, NSW, Australia

DOI: https://doi.org/10.1177/1534735415622013
Journal volume & issue: Vol. 16

Abstract

Read online

Clinical studies with patients with early hematological malignancies (ie, monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, or stage 0/1 chronic lymphocytic leukemia) suggest that early intervention with curcumin, derived from the spice turmeric, may lead to prolonged survival and delay in progressive disease in some of these patients.

Published in Integrative Cancer Therapies

ISSN: 1534-7354 (Print); 1552-695X (Online)
Publisher: SAGE Publishing
Country of publisher: United States
LCC subjects: Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Website: https://journals.sagepub.com/home/ict

About the journal